Femasys is trading 5% down at $2.17 after investors digested the August 14, 2026 quarterly results, with Q2 sales falling 18.9% year over year to $331,827 versus reported consensus of $1.16 million.
- EPS was $1.33 worse than the $1.13 estimate.
- The subsequent $30 million private placement improves liquidity, but weak commercial revenue appears to outweigh that benefit.
- Trading reflects live intraday activity; no reliable volume data was identified.